In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 15.63 above Avalo Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Quick Ratio than Avalo Therapeutics Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 132, from total ranking in the second quarter 2026 at 492.

Explain Quick Ratio?
How much Cash & cash equivalents AVTX�s has?
What are AVTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AVTX/financial-strength

https://api.csimarket.com/api/v1/companies/AVTX/fundamentals

https://api.csimarket.com/api/v1/companies/AVTX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

AVTX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	215.29 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	251.78 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	15.63	Subscribe	Subscribe	Subscribe	Subscribe
AVTX's Total Ranking	# 132	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	1.84 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-50.08 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 14
Healthcare Sector	# 22
Overall Market	# 132

Quick Ratio Statistics
High	Average	Low
31.89	3.5	0.12
(Jun 30 2026)		(Jun 30 2018)

Financial Statements
Avalo Therapeutics Inc 's Current Liabilities	$ 25 Millions	Visit AVTX's Balance sheet
Avalo Therapeutics Inc 's Cash & cash equivalent	$ 393 Millions	Visit AVTX's Balance sheet
Source of AVTX's Sales		Visit AVTX's Sales by Geography

Cumulative Avalo Therapeutics Inc 's Quick Ratio

AVTX's Quick Ratio for the trailling 12 Months

AVTX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	96.06 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	180.74 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	18.3	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 583	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	30.01 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	26.06 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to AVTX Financial Strength Comparisons >> Go to Compare AVTX Quick Ratio to its Competitors

News about Avalo Therapeutics Inc Quick Ratio

Avalo Therapeutics Inc. Boosts Portfolio with Acquisition and Secures $185 Million in Funding

Avalo Therapeutics Inc. Bolsters Pipeline with Acquisition of AVTX-009 and Secures $185 Million in Private Placement Funding
In a recent press release, Avalo Therapeutics Inc. (Nasdaq: AVTX) announced the acquisition of a Phase 2-ready anti-IL-1 mAb, known as AVTX-009, through the purchase of AlmataBio, Inc. This strategic move will allow Avalo to expand its portfolio in the treatment of hidradenitis suppurativa (HS) and other chronic inflammatory indications. The company also revealed plans to conduct a Phase 2 trial for HS, with topline results expected in 2026, funded by the upcoming private placement financing.
Speaking of financing, Avalo has entered into a definitive agreement for a private placement led by Commodore Capital and TCGX, along with other prominent investors such as BVF Partners, Deep Track Capital, OrbiMed, Petrichor, and RA Capital Management. This financing will provide up to $185 million in gross proceeds, with an initial upfront investment of $115.6 million. After deducting transaction costs, Avalo expects to receive approximately $105 million in net upfront proceeds.

On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $25.14 millions, cumulative Quick Ratio decreased to 18.3 above the AVTX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 411 other companies have achieved higher Quick Ratio than Avalo Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2724 to 3250.

Explain Quick Ratio?
How much Cash & cash equivalents AVTX�s has?
What are AVTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 412
Healthcare Sector	# 835
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.04	1.93	0.2
(Sep 30 2025)		(Sep 30 2018)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Bicara Therapeutics Inc	40.75	$ 442.346 Millions	$ 10.856 Millions
Tango Therapeutics Inc	38.85	$ 977.503 Millions	$ 25.164 Millions
Trevi Therapeutics Inc	38.05	$ 299.408 Millions	$ 7.869 Millions
Fulcrum Therapeutics Inc	35.70	$ 306.545 Millions	$ 8.587 Millions
Boundless Bio Inc	33.60	$ 62.894 Millions	$ 1.872 Millions
Avalyn Pharma Inc	32.64	$ 422.814 Millions	$ 12.955 Millions
Immix Biopharma Inc	30.89	$ 336.303 Millions	$ 10.889 Millions
Minerva Neurosciences Inc	30.46	$ 76.945 Millions	$ 2.526 Millions
Contineum Therapeutics Inc	30.45	$ 244.484 Millions	$ 8.028 Millions
Latigo Biotherapeutics, Inc.	28.73	$ 401.241 Millions	$ 13.964 Millions
Amylyx Pharmaceuticals Inc	26.44	$ 768.132 Millions	$ 29.048 Millions
Climb Bio Inc	25.98	$ 205.423 Millions	$ 7.906 Millions
Prothena Corporation Public Limited Company	23.73	$ 271.368 Millions	$ 11.434 Millions
Innoviva Inc	22.67	$ 1,134.297 Millions	$ 50.030 Millions
Kailera Therapeutics Inc	21.40	$ 901.454 Millions	$ 42.116 Millions
Cryoport inc	20.47	$ 653.343 Millions	$ 31.911 Millions
Roivant Sciences Ltd	20.30	$ 5,683.045 Millions	$ 279.911 Millions
Disc Medicine Inc	19.87	$ 682.816 Millions	$ 34.360 Millions
Relmada Therapeutics Inc	19.30	$ 202.123 Millions	$ 10.474 Millions
Mbx Biosciences Inc	19.14	$ 481.594 Millions	$ 25.167 Millions
Telomir Pharmaceuticals Inc	19.07	$ 4.516 Millions	$ 0.237 Millions
Equillium Inc	18.92	$ 53.322 Millions	$ 2.819 Millions
Onkure Therapeutics Inc	18.58	$ 163.305 Millions	$ 8.789 Millions
Alto Neuroscience Inc	17.90	$ 319.344 Millions	$ 17.836 Millions
Upstream Bio Inc	17.34	$ 207.365 Millions	$ 11.960 Millions
Siga Technologies Inc	17.27	$ 116.380 Millions	$ 6.738 Millions
Arrivent Biopharma inc	16.86	$ 393.691 Millions	$ 23.357 Millions
Keros Therapeutics Inc	16.36	$ 259.464 Millions	$ 15.858 Millions
Design Therapeutics Inc	16.36	$ 208.608 Millions	$ 12.753 Millions
Whitehawk Therapeutics Inc	16.25	$ 169.672 Millions	$ 10.441 Millions

Date modified: 2026-11-06T12:59:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.